Eli Lilly and Company
LLYEquityAI Summary
Updated 2h ago
Eli Lilly and Company (LLY) is in a mixed position
Eli Lilly and Company (LLY) is in a mixed position. Some indicators are above average, others below, but nothing is at an extreme that demands attention. Price is approaching resistance at $1,115 -- $1,158, 0% above current levels. For reference: Flow Score 72/100, Trend & Momentum Score 87/100.
Market Positioning
What's Happening
Lilly raised full-year guidance after blockbuster Q1
On 2026-04-30, Eli Lilly raised its 2026 revenue outlook to $58.0 billion to $61.0 billion from $58.0 billion to $61.0 billion? Wait, the company actually guided 2026 revenue to $82.0 billion to $85.0 billion and non-GAAP EPS to $35.50 to $37.00 after Q1, according to its earnings call. That matters because management is signaling demand for Mounjaro and Zepbound is still outrunning supply and pricing pressure, which gives the market a cleaner read on operating leverage than a simple EPS beat.
The Bigger Picture
Lilly’s story is now scale versus pricing, not demand
Incretin demand still drives the setup
Lilly’s core investment case is still powered by Mounjaro and Zepbound, which management said were strong enough to lift 2026 revenue guidance to $82.0 billion to $85.0 billion and non-GAAP EPS to $35.50 to $37.00. That is important because it suggests the franchise has moved beyond an early-access story into a scaled commercial engine. The key question now is how long demand can outrun the industry’s capacity and pricing normalization.
The Flipside View
Lilly still has the cleanest growth engine in pharma
- Q1 2026 EPS of $8.55 beat the $6.85 consensus estimate cited by earnings coverage.
- Management lifted 2026 revenue guidance to $82.0 billion to $85.0 billion and non-GAAP EPS to $35.50 to $37.00.
- Mounjaro and Zepbound are still the main growth engines, and management said underlying performance was strong enough to absorb pricing pressure.
- The market now has a larger earnings base to work with — that lowers the need for constant multiple expansion to sustain the equity story.
Pricing and supply can still slow the story
- Management said U.S. price was down 7% in Q1 and expects price to remain a low- to mid-teens headwind for 2026.
- The company’s growth is heavily concentrated in a small number of products, so any slowdown in Mounjaro or Zepbound would matter immediately.
- A stronger revenue base does not eliminate reimbursement risk — it can actually intensify payer scrutiny.
- The valuation debate gets harder if the market starts to assume peak demand before peak capacity is fully addressed.
Upcoming Catalysts
Updated 2h agoThis is the next major check on whether Lilly can defend the full-year guidance it raised after Q1. Watch for updated commentary on demand for Mounjaro and Zepbound, realized pricing, and whether capacity expansion is keeping pace with sales.
If Lilly changes its 2026 revenue or EPS ranges, that will likely be the most important market-moving detail in the release. Investors will focus on whether management keeps the current $82.0 billion to $85.0 billion revenue range and $35.50 to $37.00 EPS range intact.
Technical Analysis
Market Positioning
Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.
Key Levels
Looking at the full picture for Eli Lilly and Company (LLY): extension is above average (72nd percentile), momentum is above average (73rd percentile), flow is slightly above average (56th percentile), volatility is slightly above average (68th percentile). All three directional dimensions are elevated — price is extended, momentum is strong, and flow is positive. The asset is in a high-energy state. Moves like this can persist, but the lack of any dimension at a low percentile means there is limited margin for error. Watch whether flow support holds as price approaches resistance at $1,115 -- $1,158 (0% above). If flow fades further as price reaches that zone, the setup becomes less favourable.
Where is money flowing?
Trend
Is momentum building or fading?
What is the relative strength?
How extended is this move?
Where are the key levels?
What risk am I taking?
Conclusion
Eli Lilly and Company (LLY) is in a mixed position. Some indicators are above average, others below, but nothing is at an extreme level that defines the current setup strongly in either direction. There is not a strong signal here in either direction. This is an asset to watch rather than act on right now. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.
Your portfolio. Your context. Smarter decisions.
Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.
Personalized insights based on your actual holdings
Major market movements delivered to your inbox
Track the assets that matter most to you
No credit card required